Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

89.49 -0.35 (-0.39%)
Official Closing Price Updated: 7:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,702,043
Open 89.34
Bid (Size) 89.35 (1)
Ask (Size) 90.66 (1)
Prev. Close 89.84
Today's Range 89.27 - 89.99
52wk Range 74.09 - 94.26
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Could This Be Novartis' Next Blockbuster Medicine?
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug. 
Via The Motley Fool
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment. 
Via MarketBeat

Performance

YTD
-2.95%
-2.95%
1 Month
-2.30%
-2.30%
3 Month
+10.30%
+10.30%
6 Month
+4.51%
+4.51%
1 Year
+4.17%
+4.17%

More News

Read More
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Via Benzinga
3 Drug Stocks With Promising Pipelines for 2023
Via InvestorPlace
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
Via Benzinga
Hopeful Golden Cross Forms On Novartis's Chart
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
A Bullish Sign Appears On Novartis's Chart
Via Benzinga
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
Via Benzinga
National Advertising Division Finds Novartis Breast Cancer Drug Claim Supported in Physician-Directed Messaging, But Not in Ads to Consumers
Via iCrowdNewswire
Drug Delivery Market – Major Technology Giants in Buzz Again : Johnson & Johnson, Sanofi, Pfizer
Via SBWire
Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028
Via SBWire
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units
Via Benzinga
3 Biotech Companies to Watch in 2023
Via InvestorPlace
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Via Investor's Business Daily
2 Top Biotech Stocks to Buy Right Now
Via The Motley Fool
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
Via Benzinga
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
Via The Motley Fool
Elon Musk Tells Employees Tesla Will Be 'Most Valuable Company On Earth, Sam Bankman-Fried Set To Enter Plea On Fraud Case, Twitter 'Should Feel Faster': Today's Top Stories
Via Benzinga
Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Ridiculously Cheap Dividend Stocks That Yield More Than 3%
Via The Motley Fool
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
Via Benzinga
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Via MarketBeat
Pfizer, Novartis Are Among Overbought Healthcare Stocks: Are They Worth A Look?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.